

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN PNEUMATIC COMPRESSION
DEVICES AND COMPONENTS THEREOF**

Investigation No. 337-TA-1316

**NOTICE OF A COMMISSION DETERMINATION NOT TO REVIEW
AN INITIAL DETERMINATION PARTIALLY TERMINATING THE
INVESTIGATION WITH RESPECT TO CERTAIN RESPONDENTS DUE TO A
SETTLEMENT AGREEMENT AND WITHDRAWAL OF THE COMPLAINT**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 14) issued by the presiding administrative law judge (“ALJ”) partially terminating the investigation with respect to certain respondents due to a settlement agreement and withdrawal of the complaint.

FOR FURTHER INFORMATION CONTACT: Carl P. Bretscher, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone (202) 205-2382. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on June 6, 2022, based on a complaint, as supplemented, filed by Precision Holdings USA Inc. of Rocklin, California, and Innovamed Health LLC of San Antonio, Texas (collectively, “Complainants”). 87 FR 34299-300 (June 6, 2022). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, sale for importation, or sale in the United States after importation of certain pneumatic compression devices and components thereof by reason of infringement of certain claims of U.S. Patent Nos. 10,058,475 and 10,912,704. *Id.* The complaint further alleges that a domestic industry exists. *Id.*

The Commission’s notice of investigation named the following respondents: Manamed. Inc. of Las Vegas, Nevada (“Manamed”); Grandway Healthcare Ltd. of Hong Kong S.A.R., China (“Grandway”); Medline Industries, Inc. of Northfield, Illinois (“Medline”); and Vive

Health LLC (d/b/a Coretech) of Naples, Florida (“Vive Health”). *Id.* at 34300. The Office of Unfair Import Investigations (“OUII”) is also a party to this investigation. *Id.*

On September 15, 2022, Complainants moved to terminate the investigation as to ManaMed, Medline, and Grandway. Manamed, Medline, and Grandway indicated they do not oppose the motion. Vive Health did not file a response. On September 23, 2022, OUII filed a response in support of Complainants’ motion but requested additional information regarding the potential impact of the settlement on the public health and welfare. On October 4, 2022, Complainants filed the requested information.

On October 7, 2022, the presiding ALJ issued the subject ID (Order No. 14) granting Complainants’ motion to partially terminate the investigation with respect to ManaMed, Medline, and Grandway due to settlement and withdrawal of the complaint. First, the ALJ granted Complainants’ motion to terminate ManaMed on the basis of a settlement agreement, which purportedly resolves all disputes between the parties. Second, the presiding ALJ granted the motion to terminate Medline and Grandway as third-party beneficiaries of the settlement agreement between Complainants and Manamed based on withdrawal of the complaint. The ALJ further found that Complainants had satisfied the requirements of Commission Rule 210.21(a), (b) (19 CFR 210.21(a), (b)) by providing a copy of the settlement agreement and stipulating that there are no other agreements, oral or written, express or implied, between Complainants and Manamed, Medline, and Grandway regarding the subject matter of the investigation. The presiding ALJ further found that public policy generally favors settlement to preserve public and private resources, and settlement would not harm the public health and welfare, competitive conditions in the U.S. economy, the production of like or directly competitive articles in the United States or U.S. consumers.


No party filed a petition for review of the subject ID.

The Commission has determined not to review the subject ID. Accordingly, ManaMed, Medline, and Grandway are terminated from this investigation.

The Commission vote for this determination took place on October 31, 2022.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read "Katherine M. Hiner". The signature is written in a cursive, flowing style.

Katherine M. Hiner

Acting Secretary to the Commission

Issued: November 1, 2022